Navigation Links
Genzyme Announces Results of Clinical Trials Investigating Powder,Form of Sevelamer Carbonate

CAMBRIDGE, Mass., June 18, 2007 /PRNewswire-FirstCall/ -- Genzyme Corp. today announced the results of two new studies comparing a powder form of Renvela (sevelamer carbonate) to Renagel tablets (sevelamer hydrochloride), including one trial in which patients received the powder form three times per day, and one in which it was administered once per day.

Genzyme is developing Renvela in powder form to provide an additional option for patients with chronic kidney disease in managing their phosphate levels. A New Drug Application for Renvela tablets is already on file with the FDA, and previous studies have shown that the tablet formulation provides equivalent phosphate control to Renagel in patients on dialysis and significant phosphorus control in patients with chronic kidney disease who are not on dialysis. Today's results are the first from trials comparing the efficacy of the powder form of Renvela to Renagel tablets.

In the first powder trial, patients treated with the powder form of Renvela three times per day experienced equivalent phosphorus control to patients treated with Renagel tablets three times per day. As a result, this trial successfully met its primary endpoint.

In the second trial, patients dosed with the powder form of Renvela once per day and those treated with Renagel tablets three times per day achieved statistically significant reductions in serum phosphorus, with both groups reaching target levels for phosphorus control outlined in the K/DOQI treatment guidelines. Phosphorus levels in the Renagel arm (4.6 mg/dL) were lower than those in the Renvela arm (5.3 mg/dL), and this trial did not achieve its primary endpoint of demonstrating non-inferiority of Renvela powder dosed once per day to Renagel tablets dosed three times per day.

In both trials, the safety profile of Renvela was consistent with the previous clinical experience of patients on dialysis using Ren
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
5. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:9/19/2014)... Conn. , Sept. 19, 2014 UBM ... , a leading online community to help oncologists and ... information available regarding the use of targeted therapies and ... cancer research and treatment.  Every September, ... a way to raise awareness about blood cancers—helping to ...
(Date:9/19/2014)... -- According to market research report, ... & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, Surgical Procedure, ... Geography - Global Trends & Forecast to 2019", ... market on the basis of various types, applications, ... market size of each of these segments in ...
(Date:9/19/2014)... DIEGO , Sept. 19, 2014  Lpath, ... leader in bioactive lipid-targeted therapeutics, announced today that ... 3,605,042 registered shares of common stock and 3,605,042 ... combined purchase price for one registered share of ... one unregistered share of common stock will be ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3
... NEW YORK, Nov. 10 Reportlinker.com announces that ... in its catalogue. , Infections ... http://www.reportlinker.com/p0161914/Infections-Ear-Infections.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire , Life Science Analytics, ... the current drug pipeline. This report provides ...
... JumpStart Inc., the Northeast Ohio venture development ... early-stage businesses, announced a JumpStart Ventures investment commitment ... of NDI Medical, the Highland Hills, OH medical ... handheld disposable nerve stimulator. , (Logo: ...
Cached Medicine Technology:Reportlinker Adds Infections Ear Infections 2Reportlinker Adds Infections Ear Infections 3JumpStart Invests in Checkpoint Surgical 2JumpStart Invests in Checkpoint Surgical 3
(Date:9/19/2014)... Dallas, TX (PRWEB) September 19, 2014 ... which introduces a traditional Scandinavian style of ... United States. Much like Diet Doc’s medical ... Diet emphasizes cooking and eating good food ... diet also focuses on teaching patients to ...
(Date:9/19/2014)... California (PRWEB) September 19, 2014 ... by technological advancements, surgical techniques, and immunosuppressant drugs ... preferred treatment for several chronic diseases related to ... in organ and tissue transplantation have phenomenally revolutionized ... Organ transplant today represents a pivotal medical ...
(Date:9/19/2014)... as Johne,s disease, is caused by the bacterium ... Austria, there is a legal obligation to report ... treatment-resistant diarrhoea and wasting among affected animals. The ... farms. The animals produce less milk, exhibit fertility ... such as udder inflammation. , To date ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 InventHelp, ... clients, an inventor from New York, has created an accessory ... from inclement weather or smoke during transport. This invention ... to a stretcher and remain in place until removed, guarding ... a more comfortable move with protection from irritating smoke or ...
(Date:9/19/2014)... as released a new blog post announcing ... for life insurance. , Clients who have heart disorders ... not require medical examinations. No medical exam life insurance ... minutes. , Some traditional policies (that require medical ... health problems, however the application time is longer and ...
Breaking Medicine News(10 mins):Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 2Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 3Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 4Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 4Health News:Lymphatic fluid used for first time to detect bovine paratuberculosis 2Health News:InventHelp® Client Patents “Patient Protector” – Designed to Protect Patients During Transport 2Health News:No Medical Exam Life Insurance For Clients Who Have Heart Problems! 2
... should reduce the salt intake to avoid high blood pressure and ... g per day//. FSA also stressed that the tinned foods should ... ,Too much of salt is very harmful to humans ... can lead to heart attacks. The amount of salt content is ...
... following ace cricketer Sachin Tendulkar's and several other players complaining ... the sports arena//. ,Tennis elbow, or lateral epicondylitis ... where the outer part of the elbow becomes painful and ... or a direct bang. The problem occurs following overuse of ...
... at high risk of fatal and non-fatal myocardial ... reason for their decreased life expectancy//. There is ... (PPAR-?) could reduce macrovascular complications. Pioglitazone is one ... ,A recent study, published in the October issue ...
... for cardiovascular disease in both men and women, which ... subjects and that 80 percent of all type 2 ... In these patients hyperglycemia per se confers ... of even borderline-high-risk LDL-C signals the need for more ...
... Odors have long been known to be capable of ... effects of essential oils have been acknowledged in folk ... lavender fragrances have been particularly attributed with mood enhancing ... the September issue of the journal Physiology & Behavior, ...
... the benefits of oral ZYVOX for the treatment of ... compared data from 80 health care clinics and compared ... The results show that oral tablets of Linezolid (ZYVOX), ... to health clinics compared to vancomycin. ,This ...
Cached Medicine News:Health News:Tennis elbow not new among cricketers, say experts 2Health News:Aromatherapy: Ambient odors of orange and lavender reduce anxiety 2Health News:Oral use of ZYVOX (Linezolid) is better to Intravenous Vancomycin use for Skin Infections 2
Precision that fits in the palm of your hand and measures down to 125 microns, the Pocket Pachymeter is about 8" X 4" x 2" and really does fit in a lab coat pocket or briefcase....
15 segment Vertical Prism Bar provides 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 25, 30 PD (Note: 30 PD is on the bar). 4447 xx Vertical Prism Bar....
Valleylab Surgistat II generator provides exceptional performance, reliability, and safety benefits in a compact, easy to use unit....
Sabre 180, 230V, 50Hz is a powerful niche generator....
Medicine Products: